‹ ›
MYP_115157
← PREVIOUS NEXT → BACK
Basic Information
MCoAA-02
Anticancer
Antimicrobial
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Standard
35 amino acids
C177H277N53O45S6
Standard
Sequence
CPKILKKCRRDSDCPGACICRYWKVCGYHLNQPFG
Physicochemical Analysis
4059.81 Da
9.10
4.78
4.43
0.1367
-0.46
0.69
-0.14
55.78
55.71
0.1143
8480.00
8855.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1582.07
-14.05
61.0
57.0
129.0
281.0
9.0
36.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0036290 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
mixed L/D amino-acid peptide [Mixed]
None
None
w=D-Tryptophane
Bio-Activity Profile
Antimicrobial Anticancer
HT-29
19.75±0.07 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0039737 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
mixed L/D amino-acid peptide [Mixed]
None
None
w=D-Tryptophane
Bio-Activity Profile
Antimicrobial Anticancer
Human red blood cells: no hemolytic activity(as show in Fig.4)
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0061785 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
mixed L/D amino-acid peptide [Mixed]
None
None
w=D-Tryptophane
Bio-Activity Profile
Antimicrobial Anticancer
PC-3
35.44±0.13 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0078420 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
mixed L/D amino-acid peptide [Mixed]
None
None
w=D-Tryptophane
Bio-Activity Profile
Antimicrobial Anticancer
MCF-7
100 μM
IC50
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/
RECORD: Rec_0347436 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
mixed L/D amino-acid peptide [Mixed]
None
None
w=D-Tryptophane
Bio-Activity Profile
Antimicrobial Anticancer Cytotoxic
PaperDual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep. 2016 Oct 13;6:35347. doi: 10.1038/srep35347. PMID: 27734947. PMID27734947 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/27734947/